Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin or Dapagliflozin+Saxagliptin vs Glimepiride in T2DM on Metformin
NCT02471404Phase 4Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin and saxagliptin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in Haemoglobin A1c at 52 weeks. Started Sep 2015; status: completed.
02
Drugs
dapagliflozinsaxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02471404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02471404.